NCT04556526View on ClinicalTrials.gov

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

PHASE3CompletedINTERVENTIONAL
Enrollment

4,031

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

March 2, 2023

Study Completion Date

March 2, 2023

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.ZEBOV

Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.

BIOLOGICAL

MVA-BN-Filo

Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.

Trial Locations (3)

780

Center for Family Health Research/Project San Francisco, Kigali

Unknown

Gihundwe District Hospital, Cuangugu

Gisenyi Hospital, Gysenyi

All Listed Sponsors
collaborator

Center for Family Health Research (CFHR)

UNKNOWN

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

Emory University

OTHER

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT04556526 - A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women | Biotech Hunter | Biotech Hunter